Patent Assignment Details
NOTE:Results display only for issued patents and published applications.
For pending or abandoned applications please consult USPTO staff.
|
Reel/Frame: | 045397/0014 | |
| Pages: | 7 |
| | Recorded: | 03/30/2018 | | |
Attorney Dkt #: | PAT057045-US-PCT |
Conveyance: | ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). |
|
Total properties:
1
|
|
Patent #:
|
|
Issue Dt:
|
06/25/2019
|
Application #:
|
15755140
|
Filing Dt:
|
02/26/2018
|
Publication #:
|
|
Pub Dt:
|
08/30/2018
| | | | |
Title:
|
A PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE CDK4/6 INHIBITOR RIBOCICLIB, AND THE USE THEREOF IN THE TREATMENT/PREVENTION OF CANCER
|
|
Assignee
|
|
|
250 MASSACHUSETTS AVENUE |
CAMBRIDGE, MASSACHUSETTS 02139 |
|
Correspondence name and address
|
|
NOVARTIS PHARMACEUTICALS CORPORATION
|
|
1 HEALTH PLAZA
|
|
EAST HANOVER, NJ 07936
|
Search Results as of:
06/14/2024 09:02 PM
If you have any comments or questions concerning the data displayed,
contact
PRD / Assignments at 571-272-3350. v.2.6
Web interface last modified:
August 25, 2017 v.2.6
|